Clinical Trial Update: Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva) [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating topical calcipotriene/betamethasone (Taclonex) for localized breakthrough psoriasis in patients receiving efalizumab (Raptiva) was term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Raptiva (efalizumab)
• TACLONEX (calcipotriol and betamethone dipropionate)

Snippet

Sponsor: Derm Research, PLLC | Conditions: Plaque Psoriasis | Phase 4 | Status: TERMINATED | Results posted: 2012-04-03